Endometrial cancer (EC) harboring heterozygous POLE proofreadinginactivating mutations (POLE-exo*) is associated with anincreased number of somatic mutations that result in a distinctive anti-tumorimmune response. This evidence concerns the gene POLE and endometrial cancer.